What insurance policy changes affect HCPCS J7345?

There are 10 tracked policy changes affecting HCPCS J7345, including updates from Aetna, Independence Blue Cross. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J7345?

Payers that have issued tracked updates for HCPCS J7345 include: Aetna, Independence Blue Cross.

How do I get notified when HCPCS J7345 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J7345. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS J7345?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

J7345 — Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg: Insurance Policy Changes

J7345 Insurance Policy Changes

HCPCS J7345 is officially defined as "Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg." HCPCS J7345 is referenced in 10 tracked payer policy changes from Aetna and Independence Blue Cross. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J7345 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Medium impact

Actinic Keratoses Treatments (CPB 0567, reviewed 2026-08-21)

Aetna·Identified Sep 29, 2026

Aetna's updated Clinical Policy Bulletin 0567 (effective 2026-08-21) clarifies coverage for actinic keratoses treatments, specifying which destructive methods (cryosurgery, topical agents, curettage/excision, and advanced therapies like laser and PDT) are medically necessary, while designating specific experimental treatments as non-covered. Billing teams must ensure claims are submitted only for covered procedures with appropriate CPT codes and medical documentation, and reject claims for experimental modalities like intense pulsed light, microneedling, and thermal PDT.

J7345 Insurance Policy Changes

Phototherapy for Acne (CPB 0656, reviewed 2025-10-03)

Phototherapy for Acne (CPB 0656, reviewed 2026-09-15)

Actinic Keratoses Treatments (CPB 0567, reviewed 2026-04-10)

MA07.056f, Photodynamic Therapy (PDT) Using Levulan® Kerastick® or Ameluz® (Aminolevulinic Acid HCl [ALA])

MA07.056f, Photodynamic Therapy (PDT) Using Levulan® Kerastick® or Ameluz® (Aminolevulinic Acid HCl [ALA])

07.07.03o, Photodynamic Therapy (PDT) Using Levulan® Kerastick® or Ameluz® (Aminolevulinic Acid HCl [ALA])

07.07.03o, Photodynamic Therapy (PDT) Using Levulan® Kerastick® or Ameluz® (Aminolevulinic Acid HCl [ALA])

MA07.056e, Photodynamic Therapy (PDT) Using Levulan® Kerastick® or Ameluz® (Aminolevulinic Acid HCl [ALA])

07.07.03n, Photodynamic Therapy (PDT) Using Levulan® Kerastick® or Ameluz® (Aminolevulinic Acid HCl [ALA])

Actinic Keratoses Treatments (CPB 0567, reviewed 2026-08-21)